<DOC>
	<DOCNO>NCT00697710</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled , sequential-cohort , dose-escalation study ass safety , tolerability , pharmacokinetics , pharmacodynamics S-777469 , CB2 cannabinoid receptor agonist , subject mild moderate atopic dermatitis .</brief_summary>
	<brief_title>A Phase Ib/IIa , Double-Blind , Randomized Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics S-777469 Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Otherwise healthy male females 18 65 year age time obtain write informed consent Subject understand study procedure agree participate study give write informed consent Subject satisfy diagnostic criterion mild moderate atopic dermatitis ( AD ) judge Physician 's Global Assessment Score modify criterion All feature must present : 1 . Pruritus 2 . Eczema ( acute , subacute , chronic ) follow characteristic : current prior flexural lesion , lesion face , neck , extensor surface , spar groin axillary region ( lesion ) 3 . History chronic relapse course eczema 4 . Personal family history atopy Subject judge general good health base medical history , physical examination , routine laboratory test perform screen baseline , exception diagnosis mild moderate AD Subject negative laboratory result hepatitis B surface antigen , hepatitis C virus ( antiHCV antibody ) , Human Immunodeficiency Virus antibody screen Female subject negative pregnancy test screen baseline Serum creatinine normal range [ 0.5 1.5 mg/dl ] Liver function test ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gamma glutamyl transpeptidase [ GGT ] ) within normal range Negative screen drug abuse screen baseline Subject agree refrain smoke duration trial Subject clinically significant abnormality screen baseline electrocardiogram ( ECG ) . Inclusion subject ECG abnormality screen baseline must jointly agree upon Study Investigator Sponsor clinically relevant within context study , prior enrollment Use adequate birth control , reproductive potential sexually active Adequate birth control define agreement consistently practice effective accept method contraception throughout duration study 1 additional month last administration/dose study drug . For female , adequate birth control method define : oral contraceptive , intrauterine device double barrier contraception , i.e. , condom + diaphragm , condom diaphragm + spermicidal gel foam For male adequate birth control method define double barrier contraception , i.e. , condom + diaphragm , condom diaphragm + spermicidal gel foam For female subject , menopause define one year without menses ; question , folliclestimulating hormone &gt; 40 U/ml must document . Hysterectomy , bilateral oophorectomy , bilateral tubal ligation must document , applicable Subject use topical systemic treatment AD 3 week prior Day 1 visit ( i.e. , washout period ) , include topical corticosteroid ( 3 week prior Day 1 visit ) , antihistamine ( 3 week prior Day 1 visit ) , herbal preparation , cosmetic emollient preparation ( 3 week prior Day 1 visit ) , immunosuppressant drug corticosteroid ( 3 week prior Day 1 visit ) , AD treatment ( include light treatment ) 3 week prior Day 1 visit Subject willing completely avoid use prescription nonprescription ( include counter ) drug topical preparation [ topical emollient preparation provide study site screening , e.g. , CetaphilÂ® cream ] 3 week prior first dose study drug entire study If subject discontinue prior medication within 3 week study start , he/she may include study Study Investigator Sponsor 's Medical Monitor agree clinically relevant within context study Use hormone replacement therapy ( postmenopausal female ) and/or use oral , implantable , transdermal , injectable contraceptive ( ) allow Subject willing avoid strenuous physical activity ( i.e. , strenuous unaccustomed weight lifting , run , exercise , etc . ) screen visit , throughout study , poststudy followup visit Subject willing avoid grapefruitcontaining products/medications 72 hour prior entry clinical research unit duration study Subject history frequent recent acetaminophen use willing refrain use acetaminophen throughout trial 4 day last dose Subjects eligible meet follow criterion : Subject age legal consent ( see inclusion criterion ) , mentally legally incapacitate , significant emotional problem time study entry , history psychiatric disorder Active dermatologic condition may confound diagnosis AD , scabies , allergic contact dermatitis , seborrheic dermatitis , cutaneous lymphoma , ichthyosis , psoriasis History malignancy remission &gt; 5 year Presence comorbid condition would preclude participation study , include : Immune compromise state , include recent chemotherapy , immunotherapy , organ transplant History clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal urological History clinical manifestation significant neurological psychiatric disorder Subject active , intercurrent infection Subject history clinically significant hypersensitivity , anaphylaxis , allergy drug compound In circumstance subject qualify inclusion criterion regard liver function test ( ALT , AST , GGT ) rescreened and/or requalified study Subject acute chronic condition prior therapy , opinion Investigator , would limit subject 's ability complete and/or participate clinical study otherwise would make subject unsuitable study Subject history drug abuse within 1 year prior Day 1 Subject consumes excess amount alcohol , define exceed average 14 drinks/week ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor , combination ) within 2 month prior Study Entry , unwilling comply restrict use alcohol screening , throughout study , study completion ( poststudy visit ) Subject use systemic antibiotic 3 week prior Day 1 visit ( washout period ) Subject pregnant lactating intend become pregnant , case male subject , intend father child study period 1 month last dose study medication Subject require use immunosuppressive drug oral corticosteroid inhale corticosteroid Subject donate blood within 6 week prior Day 1 plasma within 2 week prior screen , receive blood product within 2 month prior Day 1 Subject poor peripheral venous access Subject participate investigational study drug trial receipt investigational study drug occur within 30 day prior Day 1 Any reason , opinion investigator , interfere ability subject participate , complete , trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>